Having focused its efforts on developing and commercializing oncology tests since 2017, Biocartis NV has reached an “inflection point,” according to its CEO, and is moving into infectious disease diagnostics – a decision spurred by the COVID-19 pandemic.
The company makes the Idylla real time PCR instrument, which is capable of fully automated nucleic acid testing, including...